EUVIMEDEUVIMED entdecken
Crossref

Electrochemiluminescence Immunoassay Versus Chemiluminescence Immunoassay for Hormone Quantification in Subclinical Endocrine Disorders: A Narrative Review of Analytical Performance, Interference Profiles, and Clinical Implications

Anand Mohan, Preetha Anand

ICME JOURNAL OF LABORATORY MEDICINE · 2026 · 43-52

DOI: 10.54646/icme.2026.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ICME JOURNAL OF LABORATORY MEDICINE, 2026. Verfasst von Anand Mohan und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subclinical endocrine disorders — defined by subtle biochemical deviation from population reference intervals without overt clinical symptoms — occupy a diagnostic grey zone where laboratory platform selection carries direct therapeutic consequence. Electrochemiluminescence immunoassay (ECLIA) and chemiluminescence immunoassay (CLIA) are the two dominant automated technologies for hormone quantification in contemporary clinical laboratories. Their analytical profiles differ substantially at the low measurement concentrations that define subclinical diagnostic boundaries.

Objective

To critically compare ECLIA and CLIA across analytical performance dimensions most relevant to subclinical hormone estimation, with particular emphasis on interference susceptibility, low-range precision, operational reliability, and platform-specific matrix effects, and to derive evidence-based recommendations for platform selection and pre-analytical risk mitigation in subclinical endocrine workflows.

Methods

A structured narrative review synthesized peer-reviewed method-comparison studies, regulatory safety communications from the United States Food and Drug Administration (FDA), manufacturer validation datasets, and published clinical case series examining thyroid-stimulating hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), cortisol, testosterone, follicle-stimulating hormone (FSH), luteinising hormone (LH), and oestradiol across ECLIA (Roche Cobas/Elecsys) and CLIA (Siemens, Abbott, Beckman Coulter, Snibe) platforms.

Results

Correlation coefficients between platforms exceeded 0.90 for most analytes across full clinical ranges; however, systematic inter-platform biases emerged specifically at low-measurement concentrations critical for subclinical classification. ECLIA's structural dependence on streptavidin–biotin solid-phase capture conferred unique susceptibility to exogenous biotin, with interference thresholds documented at 30–100 ng/mL. In sandwich immunoassay configurations (TSH, FSH, LH), biotin excess produced falsely suppressed values; in competitive formats (fT4, fT3, cortisol, testosterone), spuriously elevated signals were observed — together mimicking overt biochemical hyperthyroidism. CLIA platforms employing acridinium ester direct chemiluminescence demonstrated clinically negligible interference at biotin concentrations up to 1,200 ng/mL in comparative spiking studies. ECLIA's reusable platinum electrode introduced maintenance-dependent precision instability that was most consequential at the TSH concentrations defining the subclinical range (0.5–5.0 mIU/L).

Conclusion

CLIA platforms offer superior interference resilience and operational consistency for routine subclinical hormone screening in patient populations with significant biotin exposure risk. ECLIA retains analytical advantages in dynamic range and signal amplification for high-concentration clinical scenarios where biotin interference can be excluded. Evidence-informed platform-conscious selection, systematic pre-analytical biotin screening, and dual-platform reflex testing protocols are essential for safeguarding diagnostic accuracy in subclinical endocrine practice.

Zitieren

APA

Mohan, A., & Anand, P. (2026). Electrochemiluminescence Immunoassay Versus Chemiluminescence Immunoassay for Hormone Quantification in Subclinical Endocrine Disorders: A Narrative Review of Analytical Performance, Interference Profiles, and Clinical Implications. ICME JOURNAL OF LABORATORY MEDICINE, 43-52. https://doi.org/10.54646/icme.2026.12

Vancouver

Mohan A, Anand P. Electrochemiluminescence Immunoassay Versus Chemiluminescence Immunoassay for Hormone Quantification in Subclinical Endocrine Disorders: A Narrative Review of Analytical Performance, Interference Profiles, and Clinical Implications. ICME JOURNAL OF LABORATORY MEDICINE. 2026:43-52. doi:10.54646/icme.2026.12

BibTeX
@article{Mohan2026,
  author = {Mohan, Anand and Anand, Preetha},
  title = {Electrochemiluminescence Immunoassay Versus Chemiluminescence Immunoassay for Hormone Quantification in Subclinical Endocrine Disorders: A Narrative Review of Analytical Performance, Interference Profiles, and Clinical Implications},
  journal = {ICME JOURNAL OF LABORATORY MEDICINE},
  year = {2026},
  pages = {43--52},
  doi = {10.54646/icme.2026.12}
}
Kostenlos starten →